ILab (ILAB(DRUGDISCOVERY) KS EQUITY)

The company develops small molecule immune response modulating drugs to address unmet medical needs. It focuses on the development of oral, small-molecule tumor necrosis factor (TNF) therapies designed to offer low immunogenicity for the treatment of rheumatoid arthritis and related diseases.